236 related articles for article (PubMed ID: 19597349)
1. Therapy for prion diseases: Insights from the use of RNA interference.
White MD; Mallucci GR
Prion; 2009; 3(3):121-8. PubMed ID: 19597349
[TBL] [Abstract][Full Text] [Related]
2. RNAi for the treatment of prion disease: a window for intervention in neurodegeneration?
White MD; Mallucci GR
CNS Neurol Disord Drug Targets; 2009 Nov; 8(5):342-52. PubMed ID: 19702576
[TBL] [Abstract][Full Text] [Related]
3. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.
White MD; Farmer M; Mirabile I; Brandner S; Collinge J; Mallucci GR
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10238-43. PubMed ID: 18632556
[TBL] [Abstract][Full Text] [Related]
4. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
5. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.
Pfeifer A; Eigenbrod S; Al-Khadra S; Hofmann A; Mitteregger G; Moser M; Bertsch U; Kretzschmar H
J Clin Invest; 2006 Dec; 116(12):3204-10. PubMed ID: 17143329
[TBL] [Abstract][Full Text] [Related]
6. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.
Mallucci G; Dickinson A; Linehan J; Klöhn PC; Brandner S; Collinge J
Science; 2003 Oct; 302(5646):871-4. PubMed ID: 14593181
[TBL] [Abstract][Full Text] [Related]
7. Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Prasad KN; Bondy SC
Curr Aging Sci; 2019; 11(4):216-225. PubMed ID: 30636622
[TBL] [Abstract][Full Text] [Related]
8. Neurometals in the Pathogenesis of Prion Diseases.
Kawahara M; Kato-Negishi M; Tanaka KI
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525334
[TBL] [Abstract][Full Text] [Related]
9. Gene and cell therapy for prion diseases.
Relaño-Ginés A; Gabelle A; Lehmann S; Milhavet O; Crozet C
Infect Disord Drug Targets; 2009 Feb; 9(1):58-68. PubMed ID: 19200016
[TBL] [Abstract][Full Text] [Related]
10. Fundamentals of prion diseases and their involvement in the loss of function of cellular prion protein.
Sakudo A; Ikuta K
Protein Pept Lett; 2009; 16(3):217-29. PubMed ID: 19275734
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations.
Crozet C; Lin YL; Mettling C; Mourton-Gilles C; Corbeau P; Lehmann S; Perrier V
J Cell Sci; 2004 Nov; 117(Pt 23):5591-7. PubMed ID: 15494372
[TBL] [Abstract][Full Text] [Related]
12. Prion proteins: a biological role beyond prion diseases.
Hu W; Rosenberg RN; Stüve O
Acta Neurol Scand; 2007 Aug; 116(2):75-82. PubMed ID: 17661791
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.
Singh J; Udgaonkar JB
Biochemistry; 2015 Jul; 54(29):4431-42. PubMed ID: 26171558
[TBL] [Abstract][Full Text] [Related]
14. Tackling prion diseases: a review of the patent landscape.
Zattoni M; Legname G
Expert Opin Ther Pat; 2021 Dec; 31(12):1097-1115. PubMed ID: 34134584
[No Abstract] [Full Text] [Related]
15. Metabolic aspects of prion diseases: an overview.
Vranac T; Bresjanac M
Curr Drug Targets; 2010 Oct; 11(10):1207-17. PubMed ID: 20840065
[TBL] [Abstract][Full Text] [Related]
16. Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease.
Cortez LM; Campeau J; Norman G; Kalayil M; Van der Merwe J; McKenzie D; Sim VL
J Virol; 2015 Aug; 89(15):7660-72. PubMed ID: 25972546
[TBL] [Abstract][Full Text] [Related]
17. Prions impair bioaminergic functions through serotonin- or catecholamine-derived neurotoxins in neuronal cells.
Mouillet-Richard S; Nishida N; Pradines E; Laude H; Schneider B; Féraudet C; Grassi J; Launay JM; Lehmann S; Kellermann O
J Biol Chem; 2008 Aug; 283(35):23782-90. PubMed ID: 18617522
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol transporter ATP-binding cassette A1 (ABCA1) is elevated in prion disease and affects PrPC and PrPSc concentrations in cultured cells.
Kumar R; McClain D; Young R; Carlson GA
J Gen Virol; 2008 Jun; 89(Pt 6):1525-1532. PubMed ID: 18474570
[TBL] [Abstract][Full Text] [Related]
19. Folding and misfolding of the prion protein in the secretory pathway.
Tatzelt J; Winklhofer KF
Amyloid; 2004 Sep; 11(3):162-72. PubMed ID: 15523918
[TBL] [Abstract][Full Text] [Related]
20. Human prion disease and human prion protein disease.
Kitamoto T; Tateishi J
Curr Top Microbiol Immunol; 1996; 207():27-34. PubMed ID: 8575204
[No Abstract] [Full Text] [Related]
[Next] [New Search]
